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Abstract
Background: The Wnt pathway mediates differentiation of epithelial tissues; depending on the tissue types, Wnt can either
drive or inhibit the differentiation process. We hypothesized that key genes in the Wnt pathway are suppressed in the
human airway epithelium under the stress of cigarette smoking, a stress associated with dysregulation of the epithelial
differentiated state.
Methodology/Principal Findings: Microarrays were used to assess the expression of Wnt-related genes in the small airway
epithelium (SAE) obtained via bronchoscopy and brushing of healthy nonsmokers, healthy smokers, and smokers with
COPD. Thirty-three of 56 known Wnt-related genes were expressed in the SAE. Wnt pathway downstream mediators b-
catenin and the transcription factor 7-like 1 were down-regulated in healthy smokers and smokers with COPD, as were many
Wnt target genes. Among the extracellular regulators that suppress the Wnt pathway, secreted frizzled-related protein 2
(SFRP2), was up-regulated 4.3-fold in healthy smokers and 4.9-fold in COPD smokers, an observation confirmed by TaqMan
Real-time PCR, Western analysis and immunohistochemistry. Finally, cigarette smoke extract mediated up-regulation of
SFRP2 and down-regulation of Wnt target genes in airway epithelial cells in vitro.
Conclusions/Significance: Smoking down-regulates the Wnt pathway in the human airway epithelium. In the context that
Wnt pathway plays an important role in differentiation of epithelial tissues, the down-regulation of Wnt pathway may
contribute to the dysregulation of airway epithelium differentiation observed in smoking-related airway disorders.
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Introduction
The human airway epithelium, a pseudostratified layer of cells
derived from the endoderm, serves as a physical barrier against
inhaled pathogens, xenobiotics, and other noxious substances in
the environment [1,2]. The normal airway epithelium has the
capacity of regeneration and repair [3–7]. Of the major cell types,
the airway epithelial progenitor cells are in the basal cell
population, cells capable of self renewal and differentiation into
columnar cells and eventually, the differentiated secretory and
ciliated cell populations that function to defend the airway against
environmental stress [3,7–9].
There are several lines of evidence that demonstrate controlling
this differentiation process, in part, is through the canonical Wnt/
b-catenin signaling pathway [10,11]. The canonical Wnt pathway
plays a central role in lung development and is critical for
generation of the lung epithelium [10,12–14]. Components of the
canonical Wnt signaling pathway are expressed in embryonic and
adult lung cell lines, as well as in the developing lung in a specific,
spatio-temporal pattern [11,15–17]. When canonical Wnt signal-
ing is active, the pathway maintains cells in a low differentiation
state [18–23]. However, when the canonical Wnt pathway is
suppressed, undifferentiated progenitor cells are allowed to
proceed toward differentiation [18–23]. Modulation of Wnt
expression in embryonic and adult mouse lung suggests that the
Wnt pathway is important for cell fate decisions and differentiation
of lung cell type [24,25]. The agonists of the canonical Wnt/b-
catenin pathway include multiple Wnt proteins that function
through frizzled receptors to up-regulate b-catenin, resulting in
activation of the T cell factor (LEF1, TCF7, TCF7L1, TCF7L2)
transcription factor family [26,27]. The extracellular antagonists of
Wnt signaling are the secreted fizzled-related (SFRP) and the
Dickkopf (DKK) family of proteins [28,29]. When the SFRPs
and/or DKKs are up-regulated, the Wnt pathway is suppressed,
allowing differentiation to proceed [28,29].
Based on this background, we hypothesized that the canonical
Wnt/b-catenin signaling pathway may be deranged in the airway
epithelium when it is in a state of constant stress such as in
cigarette smokers. To assess this hypothesis, we used microarrays
to survey the mRNA levels of the canonical Wnt/b-catenin
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induced lung disease [30]. Pure populations of small airway
epithelium were obtained by fiberoptic bronchoscopy of healthy
nonsmokers, healthy smokers, and smokers with established
COPD. The data demonstrate that most components of the
Wnt/b-catenin pathway are expressed in the small airway
epithelium. Interestingly, the downstream mediators b-catenin
and the TCF transcription factor TCF7L1, as well as several
downstream Wnt pathway target genes, are down-regulated in
healthy smokers and smokers with COPD. Consistent with the
down-regulation of Wnt/b-catenin pathway associated with
smoking, the mRNA and protein levels of the Wnt inhibitor
secreted frizzled-related protein 2 were greatly up-regulated in the
small airway epithelium of healthy smokers and smokers with
COPD, with expression primarily in ciliated cells. Finally, in vitro
exposure of lung epithelium to cigarette smoke extract demon-
strated similar results, with up-regulation of SFRP2 and down-
regulation of the Wnt pathway. Together, these results show that
smoking is associated with abnormal regulation of the Wnt
pathway in the airway epithelium, an observation consistent with
the disordered epithelial differentiation observed in smoking-
related airway disorders.
Methods
Study Population
All individuals were evaluated at the Weill Cornell NIH Clinical
and Translational Science Center and Department of Genetic
Medicine Clinical Research Facility using protocols approved by
the Weill Cornell Medical College Institutional Review Board. All
subjects provided written consent before any study procedures
were undertaken. Healthy nonsmokers and healthy smokers were
characterized on the basis of clinical history and physical
examination, routine blood screening tests, chest X-ray, electro-
cardiogram, urinalysis, and pulmonary function testing. Current
smoking status was confirmed by history, venous carboxyhemo-
globin levels, and urinalysis for nicotine levels and its derivative
cotinine. Smokers with established COPD were defined according
to Global Initiative for Chronic Obstructive Lung Disease criteria
[31,32].
Collection of Small Airway Epithelium
Small airway epithelium was collected using flexible bronchos-
copy as previously described [33,34]. Smokers were asked not to
smoke the evening prior to the procedure. A flexible bronchoscope
(Pentax, EB-1530T3) was advanced to the desired bronchus after
achieving mild sedation and anesthesia of vocal cords. Small
airway samples were collected from 10
th to 12
th order bronchi
using methods previously described. The airway epithelial cells
were subsequently collected separately in 5 ml of LHC8 medium
(GIBO, Grand Island, NY). An aliquot of this was used for
cytology and differential cell count and the remainder was
processed immediately for RNA extraction. Total cell counts were
obtained using a hemocytometer while differential cell counts were
determined on sedimented cells prepared by centrifugation
(Cytospin 11, Shandon Instruments, Pittsburg, PA) and stained
with DiffQuik (Baxter Healthcare, Miami, FL).
RNA Extraction and Microarray Processing
Microarray analysis was performed using Affymetrix (Santa Clara,
CA) microarray HG-U133Plus2.0 (54,675 probe sets)and associated
protocols. Total RNA was extracted from epithelial cells using
TRIzol (Invitrogen, Carlsbad, CA) followed by DNAnase (Qiagen,
Valencia, CA) to remove residual DNA. An aliquot of each RNA
sample was run on an Agilent Bioanalyzer (Agilent Technologies,
Palo Alto, CA) to visualize and quantify the degree of RNA integrity.
The concentration was determined using a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE).
Double-stranded complementary DNA was synthesized from 3 mg
of total RNA using the GeneChip One-Cycle cDNA Synthesis Kit,
followed by a cleanup step using GeneChip Sample Cleanup
Module. Next, an in vitro transcription (IVT) reaction was performed
with GeneChip IVT Labeling Kit after which further cleanup was
carried out and quantification of the resulting biotin-labeled cRNA
by spectrophotometry (all reagents from Affymetrix). Hybridizations
to test chips and when permissible, to the microarrays, were
conducted according to Affymetrix protocols. The Affymetrix
GeneChip Fluidics Station 450 was used for processing the arrays
with appropriate reagents/washes, prior to scanning with an
Affymetrix GeneChip Scanner 3000 7G (http://affymetrix.com/
support/technical/manual/expression_manual.affx).
Captured images were analyzed using Microarray Suite version
5.0 (MAS 5.0) algorithm (Affymetrix) as previously described.
Samples used for analysis were required to satisfy quality control
criteria including: (1) RNA Integrity Number (RIN) $7.0; (2) 39/
59 ratio for GAPDH#3; and (3) scaling factor #10.0 [35]. This
data were normalized using GeneSpring version 7.3 software
(Agilent Technologies, Palo Alto, CA) per array, by dividing the
raw data by the 50
th percentile of all measurements. The data sets
were assessed for expression of 56 Wnt signaling pathway genes
and 55 Wnt target genes (based on the Wnt homepage, http://
www.stanford.edu/,rnusse/wntwindow.html) using criteria of
present (P call) of .20% of healthy nonsmokers.
TaqMan RT-PCR Confirmation of Microarray Expression
Levels
To confirm the microarray findings, TaqMan real-time RT-
PCR was performed on RNA samples from the small airway
samples of healthy nonsmokers, healthy smokers and smokers with
COPD (n=9 each, except for b-catenin, n=11 each) that had
been used for HG-U133 Plus 2.0 microarray analysis. First, cDNA
was synthesized from 2 mg RNA in a 100 ml reaction volume,
using the TaqMan Reverse Transcriptase Reaction Kit (Applied
Biosystems), with random hexamers as primers. Dilutions of 1:10
and 1:100 were made from each sample and triplicate wells were
run for each dilution. TaqMan PCR reactions were carried out
using primers (Applied Biosystems, Foster City, CA), and 2 mlo f
cDNA was used in each 25 ml reaction volume. The endogenous
control was 18S ribosomal RNA and relative expression levels
were determined using the DDCt method (Applied Biosystems).
The rRNA probe was labeled with VIC and the probe for each
gene of interest (b-catenin, TCF7L1, SOX9, MMP7) was labeled
with FAM. The PCR reactions were run in an Applied Biosystems
Sequence Detection System 7500.
Western Analysis
Western analysis was used to quantitatively assess SFRP2 protein
expression in small airway brushing samples from healthy
nonsmokers, healthy smokers and smokers with COPD. Red blood
cells were lysed (red blood cell lysis buffer, eBioscience, San Diego,
CA), and proteins were extracted using RIPA buffer (Sigma-
Aldrich, Saint Louis, MO) following the manufacture’s instructions.
Protein concentrations were assessed using a bicinchoninic acid
(BCA) protein concentration kit (Pierce, Rockford, IL). Equal
concentration of protein mixed with NuPAGE LDS Sample Buffer
and NuPAGE Reducing Agent was heated at 70uC for 10 min.
Then samples were loaded on NuPAGE 4 to12% Bis-Tris Gel
(Invitrogen, Carlsbad, CA). Protein electrophoresis was carried out
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4uC) to a 0.2 mm PVDF membrane (Invitrogen, Carlsbad, CA) in
NuPAGE transfer buffer. The membranes were then blocked with
5% non-fat milk in Phosphate Buffered Saline with 0.1% tween-20
(PBST) for 1 hr. The membranes were incubated with primary
rabbit polyclonal anti-SFRP2 antibodies (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) at 1:200 dilution 4uC overnight. Detection
wasperformedusing secondary horseradishperoxidase-labeled goat
anti-rabbit antibody (1:2,000 dilution, Santa Cruz Biotechnology)
and then enhanced chemiluminescent reagent system (GE Health-
care, Pittsburgh, PA). To assess the Western analysis quantitatively,
the film was digitally imaged, maintaining exposure within the
linear range of detection. The contrast was inverted, the pixel
intensity of each band determined, and the background pixel
intensity for a negative area of the film of identical size subtracted
using MetaMorph image analysis software (Universal Imaging,
Downingtown, PA). The membrane was subsequently stripped and
reincubated with monoclonal anti-b-actin antibody (Sigma-Aldrich,
Saint Louis, MO) as a control for equal protein concentration.
Localization of SFRP2 in the Airway Epithelium
To determine the distribution of SFRP2 expression in small
airway epithelial cells, cytospin preparation of bronchial brushes
obtained from the small airway epithelium of healthy nonsmoker,
healthy smokers and smokers with COPD were assessed by
SFRP2-specific immunofluorescence. Sections were fixed in 4%
paraformaldehyde for 15 min, and washed twice in PBS. Samples
were blocked in normal goat serum to reduce background staining
and then incubated with the rabbit anti-human SFRP2 primary
antibody (Atlas Antibodies, Stockholm, Sweden) diluted 1:250 and
rabbit IgG (Jackson Immunoresearch, West Grove, PA) as the
isotype control at 4uC overnight. Goat anti-rabbit Cy3 conjugated
AffiniPure IgG (Jackson ImmunoResearch) at 1:50 dilution was
used as a secondary antibody for SFRP2. Nuclei were counter
Table 1. Demographics of the Study Population and Biologic Samples
1.
Parameter Healthy nonsmokers Healthy smokers COPD smokers
2
n4 7 5 8 2 2
Sex (male/female) 33/14 38/20 18/4
Age (yr) 41.9611.4 42.967.2 51.568.5
Race (B/W/O)
3 23/18/6 35/14/9 8/9/5
Smoking history (pack-yr) - 27.5616.6 40.9628.2
Urine nicotine (ng/ml) - 129861676 111461132
Urine cotinine (ng/ml) - 12466965 13576598
Blood carboxyhemoglobin (%) 0.460.7 1.861.9 3.062.0
Pulmonary function parameters
4
FVC 107614 109613 97620
FEV1 106615 107614 74621
FEV1/FVC 82668 0 656 1 69
TLC 101613 100612 102622
DLCO 99615 94611 75619
Gold stage (I/II/III)
2 - - 9/11/2
Medication use
b-agonist - - 7
Anticholinergic - - 2
Inhaled corticosteroid - - 3
Epithelial cells
5
Number recovered610
6 6.462.9 7.263.0 6.763.2
% epithelial cells
6 99.361.1 99.161.3 98.961.4
% inflammatory cells 0.761.1 0.861.3 1.161.4
Differential cell count
Ciliated (%) 7467.4 65.7612.4 63.5610.9
Secretory (%) 6.763.5 9.164.5 11.965.6
Basal (%) 11.165.3 12.766.6 11.966.3
Undifferentiated (%) 7.363.2 11.966.6 11.663.7
1Data are presented as mean 6 standard deviation.
2Smokers with ‘‘established COPD’’ defined by the GOLD criteria [31,32]; the COPD smoker group included: GOLD I n=9, GOLD II n=11, and GOLD III n=2.
3B=black, W=white, O=other.
4Pulmonary function testing parameters are given as % of predicted value with the exception of FEV1/FVC, which is reported as % observed; FVC - forced vital capacity,
FEV1 - forced expiratory volume in 1 sec, TLC - total lung capacity, DLCO - diffusing capacity. For individuals with COPD, FVC, FEV1, and FEV1/FVC are post-
bronchodilator values.
5Small airway epithelium.
6As a % of small airway epithelium recovered.
doi:10.1371/journal.pone.0014793.t001
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dilution; Invitrogen, Carlsbad, CA). Images were captured using
an Olympus IX 70 fluorescence microscope with 60-fold
magnification. Images were analyzed using MetaMorph software
(Universal Imaging Corporation, Downingtown, PA).
As a further assessment at the morphologic level, bronchial
biopsies from large airway of healthy nonsmokers, healthy smokers
and smokers with COPD were assessed by immunofluorescence
for SFRP2. Sections were deparaffinized and rehydrated through
a series of xylenes and alcohol. Further staining procedures were as
described above.
Colocalizations of SFRP2 with a ciliated cell-specific marker b-
tubulin IV, secretory cell-specific marker mucin 5AC and
neuroendocrine-specific marker chromogranin A were also per-
formed with cytospin preparations and biopsies. The following
antibodies were used: for b-tubulin IV, mouse monoclonal anti-
human b-tubulin IV (1:2000; Biogenex, San Ramon, CA) and
mouse IgG as the isotype control (Sigma, St Louis, MO); for mucin
5AC, mouse monoclonal (CLH2) anti-human mucin 5AC (1:50;
Vector Laboratories, Burlingame, CA) and mouse IgG as the
isotype control (Sigma, St Louis, MO); for chromogranin A, mouse
monoclonal (LK2H10+PHE5) anti-human chromogranin (1:500
dilution; Thermo Scientific, Waltham, MA) and mouse IgG as the
isotype control (Sigma, St Louis, MO). Following incubation with
the primary antibodies, goat anti-rabbit Cy5 (Jackson ImmunoR-
esearch) was used as a secondary antibody for SFPR2 and goat anti-
mouse Cy3 (Jackson ImmunoResearch) was used as a secondary
antibody for b-tubulin IV, mucin 5AC and chromogranin A.
Further staining procedures were as described above.
Down-regulation of Wnt Pathway Target Genes in
Human Small Airway Epithelial Cells Exposed to Cigarette
Smoke Extract In Vitro
Aqueous cigarette cell extract (CSE) was generated from the
combustion of 1 cigarette (Marlboro Red) bubbled through 12.5 ml
of culture medium [36]. This medium, defined as ‘‘100% CSE,’’
was adjusted to pH 7.4 and filtered through a 0.22 mm filter.
Different concentrations of CSE diluted with the culture medium
were employed, ranging from 0.1 to 20%. The human airway
epithelial cell line 16HBE [37] wasexposedto freshlyprepared CSE
for 72 hr. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-
Figure 1. The Wnt pathway expression in the small airway epithelium of human healthy nonsmokers. A. Schematic of the pathway,
showing which (in bold) ligands, soluble antagonists, receptors, co-receptors, intracellular activators, transcription factors and downstream effectors
are expressed. B. Gene expression in canonical Wnt b-catenin pathway in healthy nonsmokers in small airway epithelium. Small airway epithelium
from 47 normal nonsmokers were analyzed using the HG-U133 Plus 2.0 array and expression level normalized by chip only is plotted. Error bars
represent the standard error.
doi:10.1371/journal.pone.0014793.g001
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Science) [38]. Viability was expressed as percentage of the values
(corresponding to 100%) of untreated cells. SFRP2, MMP7, SOX9
gene expression was assessed with TaqMan real-time PCR.
Wnt Reporter Assay
HEK293 cells were transiently transfected with the reporter
construct Topflash or Fopflash (kindly provided by R. Moon,
University of Washington, Seattle) using Lipofectamine LTX
( I n v i t r o g e n ,C a r l s b a d ,C A )[ 3 9 ] .T he Topflash construct contains 8
Tcf/Lef binding sites upstream of a minimal TA viral promoter and
the firefly luciferase cDNA. The Fopflash construct is identical except
that it contains mutated copies of TCf/Lef binding sites and is used as
a control for measuring nonspecific activation of the reporter
construct. Expression of Renilla luciferase provides an internal control
value to which expression of the experimental firefly luciferase reporter
gene will be normalized. The experiment was divided into 6 groups:
Topflash plus CMV-renilla; Fopflash plus CMV-renilla; Topflash plus
CMV-renilla plus WNT1; Fopflash plus CMV-renilla plus WNT1;
Topflash plus CMV-renilla plus WNT1 plus SFRP2; Fopflash plus
CMV-renilla plus WNT1 plus SFRP2. After 48 hr, luciferase activities
were determined using the Dual Luciferase Assay System (Promega)
on a tube luminometer (Berthold detection systems).
Statistical Analysis
HG-U133 Plus 2.0 microarrays were analyzed using GeneSpring
software. Average expression values were calculated from normal-
ized expression levels for healthy nonsmokers, healthy smokers, and
smokers with COPD. p values were obtained using Benjamini-
Hochberg correction to limit the false positive rate. Statistical
comparisons between continuous variables were calculated using an
unpaired, two-tailed t-test with unequal variance. Statistical
comparisons for categorical data were achieved using Chi-squared
test. A p value,0.05 was considered significant. p values for
TaqMan data were calculated using two-tailed Student’s t-test.
Web Deposition of Data
All MIAME-compliant microarray data have been deposited in the
Gene Expression Omnibus (GEO) site (http://www.ncbi.nlm.nih.
gov/geo), which is curated by the National Center for Bioinformatics.
Accession number for small airways HG-U133 Plus 2.0 is GSE19407.
Results
Study Population
Small airway samples from a total of 127 individuals, including 47
healthy nonsmokers, 58 healthy smokers and 22 smokers with
established COPD were analyzed with microarray HG-U133 Plus 2.0
(Table 1). There were no differences with respect to gender among the
groups (p.0.3), but the COPD smokers were older than the other
groups (p,0.05). There were no differences among groups with
regard to ancestral background (p.0.3). All individuals were HIV
negative. Smokers had urine nicotine and cotinine and venous blood
carboxyhemoglobin levels confirming their current smoking status.
Sampling of Airway Epithelium
Airway epithelial cells were obtained by fiberoptic bronchoscopy
and brushing of small (10
th to 12
th order) airways. The number of cells
recovered averaged from 2.1 to 21610
6, with an average of .96%
epithelium (Table 1). The various categories of airway epithelial cells
were, as expected, from the small airway epithelium [33,34].
Expression of Wnt Signaling Pathway Genes in Small
Epithelium of Healthy Nonsmokers, Healthy Smokers and
Smokers with COPD
The genome-wide microarrays were used to analyze the gene
expression profiles of canonical Wnt signaling components at the
mRNA level in the small airway epithelium of healthy nonsmok-
ers, healthy smokers, and smokers with established COPD. In the
small airway epithelium of healthy nonsmokers, 33 of 56 (60%)
genes in the Wnt pathway were expressed (Table S1). These
expressed genes included Wnt extracellular ligands (WNT3, 4, 7B,
9A, 10A), frizzled receptors (FZD1, 3, 4, 5, 6, 7, 8), co-receptors
(LRP5, LRP6), extracellular inhibitors (SFRP2, DKK1, DKK3,
DKK4), intracellular mediators (b-catenin, GSK-3B, DVL1, 2, 3,
AES, APC1, AXIN1, AXIN2, FRAT1, FRAT2), nuclear
transcription factors (TCF7, TCF7L1, TCF7L2, LEF1). For
Wnt target genes, 27 out of 55 genes are present in small airway
epithelium, including MMP7, CLDN1, VEGFA, CCND1, SOX9,
ID2 (Figure 1A, Table S1).
In healthy nonsmokers the relative expression of WNT9A was
the most highly expressed Wnt ligand, with average expression
approximately 3.3-fold greater than WNT3, and 4.7-fold greater
Figure 2. Comparison of the relative expression of the Wnt pathway downstream and target genes in healthy nonsmokers (n=47),
healthy smokers (n=58), and smokers with COPD (n=22). Analysis was carried out with HG-U133 plus 2.0 microarrays normalized by chip and
gene. Each bar represents mean expression with standard error; * p,0.05 compared to healthy nonsmokers, * * p,0.01 compared to healthy
nonsmokers.
doi:10.1371/journal.pone.0014793.g002
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expressed receptor was FZD6, which was expressed 44.4-fold
higher than FZD7 (p,0.0001), the lowest expressed receptor. For
transcription factors in the Wnt pathway, TCF7 was the
downstream gene most highly expressed in the small airway
samples, 2.3-fold more highly expressed than TCF7L1, 4.4-fold
more than TCF7L2, and 2.7-fold more than LEF1 (p,0.0001, all
comparisons).
Compared to healthy nonsmokers, the Wnt intracellular
modulators, transcription factors and target genes were down-
regulated in healthy smokers and smokers with established COPD.
b-catenin, a central molecule in the Wnt signaling pathway, was
down-regulated 1.5-fold in healthy smokers and 1.8-fold in
smokers with COPD (both comparisons, p,0.05, Figure 2,
Table 2). Consistent with this observation, TCF7L1, a transcrip-
tion factor in Wnt pathway, was down-regulated 1.7-fold in
Table 3. Small Airway Epithelium Wnt Pathway Target Genes with Suppressed Expression in Healthy Smokers and COPD Smokers
Compared to Healthy Nonsmokers
1.
Gene symbol Gene title
Probe set
ID P call (%) Smoker/nonsmoker COPD/nonsmoker
Non-
smoker Smoker
COPD
smoker Fold-change p value Fold-change p value
SOX9 SRY (sex determining region Y)-box 9 202936_s_at 100 100 100 21.88 ,0.0001 22.29 ,0.0001
RHOU ras homolog gene family, member U 223168_at 100 100 100 21.60 ,0.0001 21.88 ,0.0001
RUNX2 runt-related transcription factor 2 232231_at 100 100 100 21.51 ,0.0001 21.32 ,0.0
JAG1 jagged 1 209099_x_at 100 100 100 21.33 ,0.0001 21.32 ,0.01
CCND1 cyclin D1 208712_at 100 100 100 21.34 ,0.0001 21.39 ,0.001
CLDN1 claudin 1 218182_s_at 98 97 86 21.37 ,0.0001 21.70 ,0.0001
CDH1 cadherin 1, type 1, E-cadherin (epithelial) 201131_s_at 100 100 100 21.25 ,0.001 21.14 NS
AXIN2 axin 2 222696_at 100 97 100 21.16 ,0.05 21.22 ,0.01
MMP7 matrix metallopeptidase 7 (matrilysin,
uterine)
204259_at 47 14 9 21.66 ,0.01 22.62 ,0.0001
ID2 inhibitor of DNA binding 2, dominant
negative helix-loop-helix protein
201565_s_at 100 100 100 21.16 ,0.05 21.12 NS
VEGFA vascular endothelial growth factor A 210512_s_at 100 100 100 21.58 ,0.05 21.17 NS
SOX2 SRY (sex determining region Y)-box 2 228038_at 100 100 100 21.12 ,0.05 21.07 NS
1NS, not significant.
doi:10.1371/journal.pone.0014793.t003
Figure 3. Comparison of the relative expression of the Wnt pathway inhibitors in healthy nonsmokers (n=47), healthy smokers
(n=58), and smokers with COPD (n=22). Analysis was carried out with HG-U133 plus 2.0 microarrays. Each bar represents mean expression with
standard error; p values are represented in brackets above the bars.
doi:10.1371/journal.pone.0014793.g003
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Figure 2, Table 2). Wnt target genes, including MMP7, VEGFA,
CLDN1, CCND1, SOX9, RHOU, were also down-regulated in
healthy smokers and smokers with COPD compared to healthy
nonsmokers (p,0.05 for VEGFA and p,0.01 for the other genes;
Figure 2, Table 3). The network of the WNT/b-catenin genes in
healthy smokers and smokers with COPD compared to healthy
nonsmokers were analyzed with Ingenuity Pathway Analysis
(Ingenuity Systems, http://www.ingenuity.com; Figure S1).
Modulation of the Wnt signaling pathway in the small airway
epithelium of healthy smokers and smokers with COPD compared
to healthy nonsmokers was verified using TaqMan PCR for
selected central genes in the pathway (Figure S2). Consistent with
microarray data, b-catenin was down-regulated 1.7-fold in
smokers compared to nonsmokers, and 1.9-fold in smokers with
COPD compared with healthy nonsmokers (p,0.05). For
transcription factors, TCF7L1 was confirmed to be down-
regulated in healthy smokers and smokers with COPD compared
to healthy nonsmokers (p,0.05). Wnt signaling pathway target
genes were also confirmed to be down-regulated. MMP7
expression decreased 7.5-fold in healthy smokers and 12.9-fold
in smokers with COPD compared to healthy nonsmokers
(p,0.05). SOX9, another Wnt target gene, was also confirmed
to be down-regulated in the small airway epithelium of healthy
smokers and smokers with COPD compared to healthy nonsmok-
ers (3.9-fold for smokers vs nonsmokers and 3.2-fold for smokers
with COPD vs nonsmokers, both p,0.01).
Expression of SFRP2 in the Small Airway Epithelium of
Healthy Nonsmokers, Healthy Smokers and Smoker with
COPD
The in vivo gene expression data showed that Wnt signaling
pathway was down-regulated in healthy smokers and smokers with
COPD compared to healthy nonsmokers in the small airway
epithelial cells. As a possible mechanism to explain this down-
regulation, we hypothesized that there may be smoking-induced
up-regulation of the SFRP and/or DKK family of extracellular
Wnt pathway inhibitors. To assess this, we analyzed Wnt
inhibitors expressed in human small airway epithelium including,
SFRP2, DKK1, DKK3 and DKK4. Interestingly, among these 4
inhibitors, SFRP2 showed significant gene expression change
between healthy smokers and healthy nonsmokers, with SFRP2
up-regulation 4.3-fold in healthy smokers and 4.9-fold in smokers
with COPD compared with healthy nonsmokers (p,0.0001,
Figure 3).
To confirm the results obtained from microarrays, anti-SFRP2
immunofluorescence and Western analysis were utilized. First,
anti-SFRP2 immunofluorescence was carried out on cytospin
preparations of small airway epithelial cells obtained from healthy
nonsmokers, healthy smokers and smokers with COPD. In all
samples, SFRP2 protein expression was detected specifically in
ciliated cells; other cell types, including secretory cells, undiffer-
entiated cells and basal cells, did not show obvious staining
(Figure 4, Figure 5). Consistent with the up-regulation of SFRP2
mRNA, qualitative immunofluorescence assessment suggested that
Figure 4. Co-localization of SFRP2 and ciliated cell specific marker b-tubulin IV. For Figures 4A–I, Cytospin preparations of airway
epithelium from a healthy smoker were stained with antibodies against SFRP2 (green), b-tubulin IV (red), Mucin 5AC (red) and chromogranin A (red).
A–C. Colocalization of SFRP2 and b-tubulin IV; D–F. Colocalization of SFRP2 and mucin 5AC; G–I. Colocalization of SFRP2 and chromogranin A. For
Figure 4J–K, biopsies from a healthy smoker were stained with antibodies against SFRP2 (red) b- tubulin IV (green). J. IgG controls of SFRP2 and b-
tubulin IV; and K. SFRP2 and b-tubulin IV co-localization.
doi:10.1371/journal.pone.0014793.g004
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COPD smokers. Second, as further confirmation, SFRP2
expression was also observed to be up-regulated in ciliated cells
of large airway biopsies (Figure 6).
To quantify this observation, Western analysis of SFRP2 was
carried out on small airway epithelial cell samples from healthy
nonsmokers, healthy smokers and smokers with COPD. This
analysis demonstrated increased SFRP2 protein expression in
healthy smokers and smokers with established COPD compared to
healthy nonsmokers in small airway epithelial cells (Figure 7,
p,0.05).
Down-regulation of the Wnt Signaling Pathway in
Human Airway Epithelial Cells Exposed to Cigarette
Smoke Extract In Vitro
To assess whether the exposure of human airway epithelial cells
to CSE would affect Wnt pathway gene expression, cultures of the
human airway epithelial cell line 16HBE were exposed to freshly
made CSE for 72 hr. Cell viability was analyzed with MTT assay
and SFRP2, MMP7 and SOX9 gene expression was analyzed
using TaqMan real-time PCR. Decreased cell viability compared
to control cells was observed with concentrations of 5, 10 and 20%
CSE. Cell viability was 100% with 0.1% CSE and 92% with 1%
CSE medium compared with controls (Figure 8A). Based on this
data, we chose 0.1% and 1% CSE for the CES in vitro exposure
studies. Compared with controls, SFRP2 gene expression
increased in a dose-dependent pattern, with 4.6-fold in 0.1%
CSE group (p,0.01) and 10.1-fold in 1% CSE groups (p,0.001)
compared to no CSE controls (Figure 7B). The Wnt target gene
MMP7 decreased 2.3-fold (p,0.05) and 4.0-fold (p,0.01)
respectively in 0.1% and 1% CSE groups compared to the
control. SOX9, another Wnt target gene, was not significant in
0.1% CSE group, but significantly decreased in 1% CSE group
(1.8-fold, p,0.05) compared to the control (Figure 8B).
Wnt Reporter Assay
To demonstrate SFRP2-dependent suppression of Wnt signal-
ing, HEK293 cells were transiently transfected with the reporter
constructs. When luciferase expression was driven by a WNT1-
dependent promoter, the co-transfection of SFRP2 in addition to
the WNT1 plasmid decreased luciferase activity in HEK293 cells
by two fold (p,0.0001, Figure S3).
Figure 5. Immunofluorescent assessment of SFRP2 expression in cytospin preparations of brushed small airway epithelium. Small
airway epithelial cell cytopreparations of healthy nonsmokers, healthy smokers and smokers with COPD were stained with anti-SFRP2 followed by a
Cy3 conjugated secondary antibody (shown in red). Nuclei were stained with DAPI (shown in blue) A–D. Healthy nonsmokers. A. IgG control; B–D.
Examples of anti-SFRP2. E–H. Healthy smokers. E. IgG control; F–H. Examples of anti-SFRP2. I–L. Smokers with COPD; I. IgG Control. J–L. Examples of
anti-SFRP2. Bar=10 mm.
doi:10.1371/journal.pone.0014793.g005
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In healthy individuals, as airway epithelial cells are injured or
reach senescence, there is ongoing cell regeneration, with basal cell
proliferation and subsequent differentiation to ciliated and
secretory cells that comprise the healthy pseudostratified epithelial
barrier that lines the airways [1–3,5]. In cigarette smokers, the
toxic components of smoke and the associated local persistent
inflammatory host response to smoking place the epithelium under
the constant stress of oxidants, apoptotic signals, and other
mechanisms of injury [40–43]. In response, the airway epithelium
regenerates at a faster rate, attempting to maintain its healthy
pseudostratified character [40,44]. To assess the role of the Wnt
pathway in the context of the stress of cigarette smoking, whole-
genome microarray was utilized to analyze expression of the Wnt
pathway genes. The data demonstrate that the majority of genes
involved in the Wnt signaling pathway, representing all functional
categories in the pathway, are expressed in the normal adult
human small airway epithelium of healthy nonsmokers, consistent
with studies showing the Wnt pathway can regulate human lung
morphogenesis [11,24,25]. With the stress of smoking, the Wnt
pathway intracellular modulators b-catenin and transcription
factor TCF7L1, as well as Wnt target genes are down-regulated,
suggesting the Wnt pathway is suppressed. Assessment of the
known extracellular inhibitors of the Wnt pathway revealed that
smoking is associated with up-regulation of SFRP2. The up-
regulated SFRP2 expression occurred in the ciliated cell
population, suggesting that the differentiated cells play a role in
modulating the ‘‘on’’ and ‘‘off’’ status of the Wnt pathway. Finally,
in vitro exposure of human airway epithelial cells to cigarette smoke
extract recapitulated the in vivo observations, with increased
SFRP2 gene expression and down-regulation of Wnt target gene
expression, demonstrating that cigarette smoke can directly down-
regulate Wnt signaling pathway in the airway epithelium.
Wnt Signaling Pathway and Lung Development
Wnt pathway signaling is an important regulator of epithelial and
mesenchymalcellbiology[26,27].Todate,thereareatleast19Wnt
ligands and 10 Fz receptor proteins identified, with redundancy and
multiplicity of the receptor interactions and the downstream
signaling [26,27]. Of the various Wnt mutant phenotypes in mice,
loss of the ligands WNT7B and WNT5A results in an abnormal
pulmonary phenotype [15,24]. Wnt7B
lacZ2/2 mice exhibit lung
hypoplasia and respiratory failure [24], and Wnt7B
lacZ2/2 embryos
and newborn mice exhibit severe defects in the smooth muscle
Figure 6. Immunofluorescent assessment of SFRP2 expression in the endobronchial biopsies from large airway epithelium.
Endobronchial biopsies from large airway of healthy nonsmoker, healthy smokers and smokers with COPD were stained with anti-SFRP2 followed by
a Cy3 conjugated secondary antibody (shown in red). Nuclei were stained with DAPI (shown in blue). A–D. Healthy nonsmokers. A. IgG control; B–D.
Examples of anti-SFRP2. E–H. Healthy smokers. E. IgG control; F–H. Examples of anti-SFRP2. I–L. Smokers with COPD. I. IgG Control, J–L. Examples of
anti-SFRP2. Bar=10 mm.
doi:10.1371/journal.pone.0014793.g006
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WNT7B signaling is required for proper lung mesenchymal growth
and vascular development [24]. Mice carrying a targeted disruption
of the WNT5A locus show abnormalities in distal lung morpho-
genesis, as manifested by truncation of the trachea and overexpan-
sion of the distal respiratory airways [15]. The overall architecture
of these mutant lungs is characterized by overexpansion of the distal
airways and inhibition of lung maturation, with a persistence of
thickened intravascular interstitium [15]. Activation of b-catenin in
mice causes ectopic differentiation of alveolar type II-like cells in
conducting airways, goblet cell hyperplasia, and air space
enlargement, suggesting a critical role for the Wnt/b-catenin signal
transduction pathway in the differentiation of the respiratory
epithelium in the postnatal lung [12].
Wnt Signaling Pathway and Lung Disease
Loss of regulation of Wnt signaling pathways has been linked to
the pathogenesis of asthma, fibrotic lung disease, nitrogen-induced
pulmonary hypoplasia and lung cancer [45–50]. Konigshoff and
colleagues [48,50] confirmed the up-regulation of WNT1,
WNT7B and WNT10B, FZD2, FZD3, b-catenin, and LEF1
expression in the lungs of individuals with idiopathic pulmonary
fibrosis compared to transplant donor lung. In vitro functional
studies have indicated that Wnt ligands induce lung epithelial cell
proliferation and (myo) fibroblast activation and collagen synthesis
[48]. Increased expression of Wnt ligands (WNT1, 2, 7A) along
with decreased expression of Wnt inhibitors (DKK3 and SFRP3)
was observed in non-small cell lung cancer [47,49,51–53].
Function of Wnt Signaling Pathway in Adult Human
Airway Epithelium
In a previous study from our laboratory, the large airway
epithelium of healthy individuals was denuded by bronchoscopy
and brushing, and genome-wide microarrays were used to study
the gene expression pattern in the same site at 0, 7 and 14 days
after injury [54]. Histologically, the injured area was completely
covered by a partially redifferentiated epithelial layer after 7 days,
and at this time point, a Wnt pathway inhibitor DKK1 was found
to be greatly up-regulated, suggesting that the Wnt/b-catenin
pathway is inhibited at this stage of airway epithelial repair [54].
In the present study, we found that the Wnt signaling pathway
was also down-regulated in adult human airway epithelium under
the stress of chronic smoking. Interestingly, using gene expression
profiling with air/whole mainstream cigarette smoke to treat a
three-dimensional air-liquid interface model of tracheobronchial
epithelium that were grown from primary human lung epithelial
cells, Maunders et al [55] showed that the Wnt signaling pathway
was down-regulated at 1, 6, and 24 hr post-exposure. For
example, at 1 hr post-treatment, 9 Wnt signaling pathway genes
and 12 Wnt target genes, including AXIN2, CCND1, JAG1,
Figure 7. Western analysis of SFRP2 protein expression in small airway epithelial cells. A. Proteins were extracted from small airway
epithelial cells of 3 healthy nonsmokers, 3 healthy smokers and 3 smokers with COPD. Shown is SFRP2 protein expression in healthy nonsmokers
(lanes 1–3), healthy smokers (lanes 4–6) and smokers with COPD (lanes 7–9). Lower panel - same membrane probed with anti b-actin antibody, a
control for protein loading. B. Quantification by densitometry of SFRP2 to b-actin. The ratio for SFRP2 to b-actin based on panel A is represented on
the ordinate for the nonsmoker, smoker and smoker with COPD. Error bars represent the standard error.
doi:10.1371/journal.pone.0014793.g007
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signaling pathway genes or Wnt target genes. This supports our in
vivo data that smoking repressed the Wnt signaling pathway. We
also showed that in vitro smokers have significant up-regulation of
another Wnt pathway inhibitor, SFRP2, an extracellular mediator
of the largest family of Wnt inhibitors. SFRP2 functions as a
modulator of Wnt signaling through direct interaction with Wnt
ligands, with consequent regulation of cell growth [28,56–64].
Inactivation of SFRP2 results in subtle limb defects in mice with
mesomelic shortening and consistent shortening of all autopodal
elements clinically manifested as brachydactyly [65]. SFRP2 has
been shown to repress canonical Wnt signaling activated by
WNT1, WNT3A, WNT4, WNT7A, and WNT9A in vitro [65–67].
Interestingly, SFRP1, another member of the SFRP family, is up-
regulated in the distal epithelial cells of the mouse lung during
development and in murine emphysema models [68]. However,
except for the function as the Wnt signaling pathway inhibitors,
recent studies showed that SFRPs are not merely Wnt-binding
proteins, but can also antagonize different SFRPs’ activity,
interfere with BMP signaling by acting as proteinase inhibitors,
decrease susceptibility to UV-induced apoptosis in primary culture
of canine mammary gland tumors by NF-kB activation or JNK
suppression, and interact with other receptors or matrix molecules
[69–74]. Because of the limitation of the primary human airway
epithelial cells, which prohibits us from performing the functional
assays of the Wnt signaling pathway in a condition similar to that
in vivo, we could not be certain that the down-regulation of Wnt
signaling in healthy smokers and COPD patients is the result of
SFRP2 up-regulation, despite the fact that SFRP2 could decrease
WNT1-induced activation of Wnt reporter luciferase activity in
HEK293 cells (p,0.05, Figure S3). Another limitation of this
study is, although the down-regulation of the Wnt signaling
pathway might induce the human airway epithelial cells to
differentiate in healthy smokers and COPD patients, in the current
study, we found there were decreased ciliated cells and increased
undifferentiated cells (Table 1). There are a number of reasons for
Figure 8. In vitro cigarette smoke extract (CES) treatment of human 16HBE airway epithelial cells. After 16HBE cells were exposed to
different concentrations of CSE for 3 days, cell viability (MTT) and gene expression levels of Wnt signaling pathway inhibitor SFRP2 and target genes
(MMP7, SOX9) were quantified using TaqMan real-time PCR. A. MTT assessment. B. Effect of CSE on gene expression of SFRP2, MMP7, SOX9 in 16HBE
cells using 0.1 and 1% CSE concentrations that do not affect viability. SFRP2 gene expression was up-regulated when treated with both 0.1 and 1%
CSE (4.6-fold and 10.1-fold, p,0.01 and p,0.001). Error bars represent the standard deviation. *p,0.05 compared to no CSE controls. For TaqMan
real-time PCR, the average value of 0.1% CSE treatment group for each gene is determined as the calibrator.
doi:10.1371/journal.pone.0014793.g008
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signaling pathway could promote the repair and differentiation
of airway epithelial cells in healthy smokers and smokers with
COPD, the effect of smoking undoubtedly has a complex effect on
multiple pathways. The confirmation of this concept is limited by
the lack of a proper in vitro model. Furthermore, because the
airway epithelial cells in vivo are composed a mixed populations
including ciliated cells, secretory cells, basal cells and other cell
populations such as clara cells, the microarray data may solely
reflect changes in cell populations from patient to patient.
However, it is unlikely because of the up-regulation of SFRP2
(which is specifically expressed in ciliated cells) in healthy smokers
and smokers with COPD as well as the fact that the healthy
smokers and smokers with COPD have lower percentage of
ciliated cells.
Our findings suggest there is a complex Wnt signaling system in
the adult human airway epithelium, which is subjected to a tightly
regulated pattern that can respond to stress. Together, the data
show that smoking induces down-regulation of Wnt signaling
pathway, consistent with the concept that in response to the stress
of cigarette smoking, the small airway epithelium Wnt pathway is
suppressed, allowing for epithelial repair and differentiation.
Supporting Information
Table S1 Expression of WNT Pathway Genes and Target
Genes in Small Airway.
Found at: doi:10.1371/journal.pone.0014793.s001 (0.12 MB
DOC)
Figure S1 Ingenuity Pathway Analysis generated WNT/b-
catenin gene network. A. IPA gene network of WNT/b-catenin
signaling pathway genes that displayed 1.5-fold or greater changes
between healthy smokers and healthy nonsmokers. B. IPA gene
network of WNT/b-catenin signaling pathway genes that
displayed 1.5-fold or greater changes between smokers with
COPD and healthy nonsmokers. Additional information about the
genes and the indicated interactions can be found at www.
ingenuity.com.
Found at: doi:10.1371/journal.pone.0014793.s002 (1.79 MB TIF)
Figure S2 TaqMan Real-time PCR confirmation of down-
regulation of selected Wnt genes and Wnt target genes in healthy
nonsmokers (NS), healthy smokers (S), and smokers with COPD
(COPD). Each bar represents mean expression with standard
error; p values are represented in brackets above the bars. The
average value of healthy nonsmokers is determined as the
calibrator for each gene.
Found at: doi:10.1371/journal.pone.0014793.s003 (0.43 MB TIF)
Figure S3 The Wnt reporter assay in HEK293 cells. HEK293
cells were transiently transfected with Wnt reporter (Topflash) or
Wnt reporter control (Fopflash) constructs, and stimulated with
WNT1 plasmid or WNT1 plus SFRP2 plasmids, as indicated. The
relative luciferase activity is plotted. The experiment was repeated
three times and representative results are presented as mean 6
standard deviation.
Found at: doi:10.1371/journal.pone.0014793.s004 (0.40 MB TIF)
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